Product Images Donepezil Hydrochloride 5 Mg
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 13 images provide visual information about the product associated with Donepezil Hydrochloride 5 Mg NDC 46708-092 by Alembic Pharmaceuticals Limited, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
10 mg-30 Tablets in HDPE Bottle Pack - donepezil 10mg
This is a medication called Donepezil Hydrochloride that comes in a film-coated tablet, with each tablet containing 10mg of the active ingredient. The instructions for dosage and use can be found in the accompanying prescribing information. It is recommended to store this medication in a tight container at a temperature of 20-25°C (68-77°F). It is manufactured by Alembic Pharmaceuticals Limited in India, with the manufacturing address and NDC number provided. The medication should only be dispensed along with the patient information sheet by a pharmacist. The lot number of the medication is not available in the text.*
5 mg-30 Tablets in HDPE Bottle Pack - donepezil 5mg
Each film-coated tablet contains 5mg of donepezil hydrochloride. This medicine should be stored in tightly closed containers between 20° to 25°C (68° to 77°F). Dosage instructions can be found in the accompanying prescribing information sheet. Dispensed by pharmacists with a prescription, and a patient information sheet should be provided. The manufacturer is Alembic Pharmaceuticals Limited, and the tablets are sold in 30-tablet quantities under the NDC 46708-092-30. The medicine has been licensed under Mfg. Lic. No.: G/959. Lot and EXP information not available.*
Figure 1 - donepezil figure1
Figure 10 - donepezil figure10
The text appears to be a graph or chart with some numerical values and medical terminology related to patients undergoing treatment. The title of the chart is "ADCS-ADL Change from Baseline" and it shows the percentage of patients completing 6 months of double-blind treatment with particular changes from baseline in ADCS-ADL-Severe Scores. Without the graph, it is not possible to give a more accurate description of the content.*
Figure 2 - donepezil figure2
Figure 3 - donepezil figure3
The text is a chart showing the percentage of patients who experienced improvement, worsening, or no change in their condition at 24 weeks, as measured by the CIBIC-plus Rating. The chart is divided into categories of marked, moderate, and minimal improvement or worsening. There is no additional information available from the text.*
Figure 4 - donepezil figure4
The text is a figure caption for a time-course graph showing the change in ADAS-cog score for patients completing a 15-week study on drug treatment. It is related to drug treatment for some condition.*
Figure 5 - donepezil figure5
Figure 6 - donepezil figure6
Figure 7 - donepezil figure7
Figure 8 - donepezil figure8
Figure 9 - donepezil figure9
Structure - donepezil structure
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.